Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (433)

Search Parameters:
Keywords = renal ischemia

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
20 pages, 1383 KiB  
Review
The Multifaceted Role of miR-211 in Health and Disease
by Juan Rayo Parra, Zachary Grand, Gabriel Gonzalez, Ranjan Perera, Dipendra Pandeya, Tracey Weiler and Prem Chapagain
Biomolecules 2025, 15(8), 1109; https://doi.org/10.3390/biom15081109 - 1 Aug 2025
Viewed by 246
Abstract
MicroRNA-211 (miR-211) is a versatile regulatory molecule that plays critical roles in cellular homeostasis and disease progression through the post-transcriptional regulation of gene expression. This review comprehensively examines miR-211’s multifaceted functions across various biological systems, highlighting its context-dependent activity as both a tumor [...] Read more.
MicroRNA-211 (miR-211) is a versatile regulatory molecule that plays critical roles in cellular homeostasis and disease progression through the post-transcriptional regulation of gene expression. This review comprehensively examines miR-211’s multifaceted functions across various biological systems, highlighting its context-dependent activity as both a tumor suppressor and oncogene. In physiological contexts, miR-211 regulates cell cycle progression, metabolism, and differentiation through the modulation of key signaling pathways, including TGF-β/SMAD and PI3K/AKT. miR-211 participates in retinal development, bone physiology, and protection against renal ischemia–reperfusion injury. In pathological conditions, miR-211 expression is altered in various diseases, particularly cancer, where it may be a useful diagnostic and prognostic biomarker. Its stability in serum and differential expression in various cancer types make it a promising candidate for non-invasive diagnostics. The review also explores miR-211’s therapeutic potential, discussing both challenges and opportunities in developing miRNA-based treatments. Understanding miR-211’s complex regulatory interactions and context-dependent functions is crucial for advancing its clinical applications for diagnosis, prognosis, and targeted therapy in multiple diseases. Full article
(This article belongs to the Special Issue DNA Damage, Mutagenesis, and Repair Mechanisms)
Show Figures

Figure 1

23 pages, 2960 KiB  
Article
Understanding the Metabolic Effects of Surgically Induced Renal Ischemia in Humans: A Temporal Approach
by Bhargav Arimilli, Tyler A. On, Vaishnavi S. Srirama, Ye Yang, Gitanjali Asampille, Jeffrey R. Brender, Murali C. Krishna, Jessica Y. Hseuh, Viraj P. Chegu, Zachary Kozel, Sandeep Gurram, Mark W. Ball, William Marston Linehan and Daniel R. Crooks
Metabolites 2025, 15(7), 462; https://doi.org/10.3390/metabo15070462 - 8 Jul 2025
Viewed by 379
Abstract
Background/Objectives: Thousands of nephrectomies are performed annually in the United States, but the short-term metabolic effects of surgically induced renal ischemia remain unclear. The conventional metabolic markers used to characterize post-surgical renal function, such as creatinine and GFR, are measured in the [...] Read more.
Background/Objectives: Thousands of nephrectomies are performed annually in the United States, but the short-term metabolic effects of surgically induced renal ischemia remain unclear. The conventional metabolic markers used to characterize post-surgical renal function, such as creatinine and GFR, are measured in the serum but do not provide metabolic information about the renal parenchyma itself. We aimed to characterize the immediate metabolic effects of surgical ischemia on renal parenchyma within a temporal framework. Methods: Timed renal parenchyma biopsies were collected from eight patients undergoing nephrectomy for renal cell carcinoma both prior to and after ligation of the renal hilum. These samples were ground, extracted, and analyzed using nuclear magnetic resonance (NMR) spectroscopy to measure changes in lactate, succinate, glucose, alanine, and glycine levels. Results: Due to experimental limitations, we were only able to draw limited conclusions from three patients. Of the five remaining patients, all had significant increases in lactate and succinate levels as a function of time, though the degree to which these increases occurred varied between each patient. Glucose levels generally decreased in the renal parenchyma but did not necessarily correlate with lactate production, assuming all glucose underwent fermentation to lactate in a hypoxic environment. Alanine and glycine levels did not change in a predictable pattern across patients. Conclusions: There are significant changes in lactate, glucose and succinate levels within minutes of the onset of renal ischemia in human patients. The degree of change in the metabolites analyzed varied significantly between patients. The length of surgical ischemia must be considered during surgical procurement of tumor specimens for metabolomic analysis. Full article
Show Figures

Figure 1

14 pages, 910 KiB  
Article
5-Year Follow-Up of Advanced Therapy Use in High-Risk Diabetic Foot Ulcers
by Margaret Doucette, Stephanie Seabolt, Kattie Payne and Jeremy Boyd
Diabetology 2025, 6(7), 61; https://doi.org/10.3390/diabetology6070061 - 1 Jul 2025
Viewed by 434
Abstract
Background/Objectives: Advanced wound healing biologics for diabetic foot ulcer (DFU) are typically withheld from persons who are at high risk for amputation. However, a prospective, single-center cohort study evaluated the use of an advanced biologic, dehydrated amniotic (DAMA) tissue as early treatment for [...] Read more.
Background/Objectives: Advanced wound healing biologics for diabetic foot ulcer (DFU) are typically withheld from persons who are at high risk for amputation. However, a prospective, single-center cohort study evaluated the use of an advanced biologic, dehydrated amniotic (DAMA) tissue as early treatment for DFUs in patients with a high risk for amputation, demonstrating benefit for a small sample. This is the report of the five-year follow-up of those high-risk participants. Methods: This chart review provides a 5-year follow-up of 18 of 20 participants in the original study. The data were collected by medical record review. Specific data points included mortality, re-ulceration and additional ulceration, amputation (minor and major), end-stage renal disease with dialysis dependence, hospitalization, and limb-threatening ischemia. Results: The 5-year mortality rate from the time of wound healing was 50% (9/18 deceased). Four of the eighteen participants (22.2%) underwent major amputation within 5 years of study completion. Two had amputations of the study limb and two had amputations of the contralateral limb. Fifty percent (2/4) of those who had amputations died within 5 years after the major amputation. Over fifty percent (55.5% or 10 out of 18) of the participants experienced the re-ulceration of the original study ulcer and 94% (17 out of 18) developed a new site ulceration. A total of 25% of the hospitalizations over the 5 years were related to DFU (infection, osteomyelitis, and sepsis). Conclusions: This small-sample 5-year follow-up shows that early treatment with dehydrated amniotic (DAMA) tissue in patients with diabetic foot ulcers of moderate-to-high amputation risk results in similar outcomes as noted in the current research on patients with low risk for amputation. In fact, this paper may suggest that advanced biologics can safely be used for early treatment in moderate-to-high amputation risk without increasing mortality and amputation over 5 years. Full article
Show Figures

Figure 1

10 pages, 308 KiB  
Article
Contemporary Outcomes of Robot-Assisted Partial Nephrectomy: Results from Two European Referral Institutions
by Francesco Barletta, Nicola Frego, Mario de Angelis, Stefano Resca, Marco Ticonosco, Enrico Vecchio, Sara Tamburini, Alessandro Pissavini, Andrea Noya Mourullo, Bin K. Kroon, Geert Smits, Bernke Papenburg, Edward Lambert, Frederick D’Hondt, Ruben De Groote, Peter Schatteman, Alexandre Mottrie and Geert De Naeyer
Cancers 2025, 17(13), 2104; https://doi.org/10.3390/cancers17132104 - 23 Jun 2025
Viewed by 413
Abstract
Introduction: Available guidelines recommend performing nephron-sparing surgery in selected renal cell carcinoma (RCC) patients. Many studies provided robot-assisted partial nephrectomy (RAPN) functional and oncological outcomes, with most of these including a wide timespan and a number of surgeons with different experiences, which might [...] Read more.
Introduction: Available guidelines recommend performing nephron-sparing surgery in selected renal cell carcinoma (RCC) patients. Many studies provided robot-assisted partial nephrectomy (RAPN) functional and oncological outcomes, with most of these including a wide timespan and a number of surgeons with different experiences, which might lead to the heterogeneity of the results. In this study, we aim to provide a contemporary report of RAPN patient outcomes performed at two referral centers by experienced surgeons. Materials and Methods: Overall, 333 RAPN patients treated at two European referral centers between 2019 and 2021 were identified. Continuous and categorical variables were reported using medians and proportions. Multi-variable logistic regression (MLR) models were fitted to test predictors of off-clamp technique use and trifecta achievement. Results: The median age was 65 (IQR: 57–73) years. The clinical stage distribution was as follows: 224 (67%) cT1a vs. 89 (26%) cT1b vs. 20 cT2 (7%). The median warm ischemia time was 14 (10–18) minutes, with trifecta being achieved in 74% (n = 240) of patients. In MLR models predicting off-clamp surgery, an increasing R.E.N.A.L. score was independently associated with a lower chance of attempting such a technique (OR: 0.69, p-value < 0.001). In models predicting trifecta achievement, both a higher R.E.N.A.L. score (OR: 0.78, p-value = 0.007) and the presence of multiple lesions (OR: 0.29, p-value = 0.007) were independently associated with lower chances of reaching the outcome. Significant upstaging of chronic kidney disease (CKD) stage was recorded in 9.4% of patients after one year of follow-up. Conclusions: We reported the contemporary outcomes of patients treated with RAPN by highly experienced surgeons from two referral centers. This report represents a valid benchmark that could be used for individual patient counseling in the decision-making process. Full article
(This article belongs to the Special Issue Clinical Treatment and Prognostic Factors of Urologic Cancer)
Show Figures

Figure 1

21 pages, 18076 KiB  
Article
Oxidized Albumin Induces Renal Tubular Cell Death and Promotes the Progression of Renal Diseases Through Ferroptosis
by Yingyu Zhang, Rui Jiang, Zhuheng Shi, Yang Sui, Jie Cheng, Mika Suda, Manabu Niimi, Kun Gao, Jianglin Fan and Jian Yao
Int. J. Mol. Sci. 2025, 26(13), 5924; https://doi.org/10.3390/ijms26135924 - 20 Jun 2025
Viewed by 417
Abstract
Oxidative stress plays a crucial role in disease pathogenesis. While reactive oxygen species (ROS) directly cause cellular injury, emerging evidence suggests oxidatively modified proteins like albumin may also contribute significantly to tissue damage. Although oxidized albumin (ox-Alb) is linked to renal pathology, the [...] Read more.
Oxidative stress plays a crucial role in disease pathogenesis. While reactive oxygen species (ROS) directly cause cellular injury, emerging evidence suggests oxidatively modified proteins like albumin may also contribute significantly to tissue damage. Although oxidized albumin (ox-Alb) is linked to renal pathology, the direct effects and mechanisms of ox-Alb on renal cell injury remain unclear. This study was created to address these questions. In mouse models of renal injury initiated by vitamin C/copper or ischemia/reperfusion, levels of serum ox-Alb were significantly elevated. The treatment of albumin with copper/vitamin C increased Alb carbonylation and reduced the number of sulfhydryl groups, causing Alb oxidation. In cultured renal tubular epithelial NRK-52E cells, ox-Alb triggered cell death, associated with increased intracellular albumin accumulation—enhanced cellular protein carbonylation, and p38 MAPK activation. Notably, ox-Alb induced ferroptosis, evidenced by decreased GPX4 and xCT, increased ACSL4, elevated iron and lipid peroxidation, and suppression by deferoxamine and liproxstatin-1. In vivo, administration of ox-Alb exacerbated doxorubicin-induced nephropathy, as indicated by the elevated BUN, creatinine, and proteinuria, and intensified renal ferroptotic responses, including altered GPX4 and ACSL4. Our findings demonstrate that ox-Alb induces renal cell ferroptosis and promotes renal disease progression, suggesting its pivotal pathogenic role in oxidative stress-related kidney diseases. Full article
(This article belongs to the Special Issue Molecular Mechanisms in Kidney Disease)
Show Figures

Figure 1

21 pages, 1156 KiB  
Review
Renal Involvement in Mixed Cryoglobulinemic Vasculitis: Current Perspectives
by Annalisa Villa, Antonietta Gigante, Chiara Pellicano, Klara Radovic, Konstantinos Giannakakis, Milvia Casato and Marcella Visentini
J. Clin. Med. 2025, 14(12), 4369; https://doi.org/10.3390/jcm14124369 - 19 Jun 2025
Viewed by 878
Abstract
Cryoglobulinemia is a rare disorder characterized by the presence of abnormal proteins (cryoglobulins) in the blood that precipitate at low temperatures. It presents with a wide clinical spectrum, from mild symptoms to severe, life-threatening disease. In mixed cryoglobulinemia (MC), vascular damage results from [...] Read more.
Cryoglobulinemia is a rare disorder characterized by the presence of abnormal proteins (cryoglobulins) in the blood that precipitate at low temperatures. It presents with a wide clinical spectrum, from mild symptoms to severe, life-threatening disease. In mixed cryoglobulinemia (MC), vascular damage results from immune complexes—typically monoclonal IgM with rheumatoid factor activity and polyclonal IgG (Type II), or polyclonal/oligoclonal IgM and IgG (Type III). These complexes can obstruct small blood vessels, leading to ischemia and leukocytoclastic vasculitis. Renal involvement occurs in about 30% of MC patients and it is a manifestation with poor prognosis. Nowadays, types II and III MC are the most common forms, often linked to autoimmune diseases like Sjögren’s syndrome and systemic lupus erythematosus, or to viral infections such as hepatitis B or persisting despite hepatitis C eradication. This review explores renal involvement in MC, offering a comprehensive perspective on current knowledge, including recent advances in pathophysiological understanding, evolving diagnostic strategies, and novel therapeutic approaches. In this context, “perspectives” refers to the growing recognition of the shifting epidemiology of MC—particularly the changing etiological landscape following hepatitis C virus eradication—as well as the integration of emerging clinical and pathological entities such as cryofibrinogenemia and monoclonal gammopathy of renal significance into diagnostic and management frameworks. Furthermore, the review highlights current therapeutic strategies recognized as most effective, emphasizing the importance of a multidisciplinary and multimodal approach that combines etiological treatment, B-cell–targeted therapy (notably rituximab), plasma exchange in selected cases, and comprehensive supportive care for renal and systemic complications. Moreover, the landscape of management could be enriched in future years, since clinical trials are ongoing to explore novel therapies for refractory or relapsing cases of MC with renal involvement. Full article
(This article belongs to the Section Nephrology & Urology)
Show Figures

Figure 1

14 pages, 3262 KiB  
Article
Functional and Oncologic Outcomes in Single-Kidney Patients Treated with Robot-Assisted Partial Nephrectomy for Renal Tumors: Results from a Prospectively Maintained Dataset of a Single Tertiary Referral Center
by Antonio Andrea Grosso, Luca Lambertini, Fabrizio Di Maida, Giulia Carli, Pedro Ramos, Alessandro Sandulli, Vincenzo Salamone, Francesca Conte, Filippo Lipparini, Elena Ciaralli, Daniele Paganelli, Sofia Giudici, Rino Oriti, Riccardo Fantechi, Matteo Salvi, Gianni Vittori, Maria Rosaria Raspollini, Gabriella Nesi, Andrea Minervini and Andrea Mari
Cancers 2025, 17(12), 1978; https://doi.org/10.3390/cancers17121978 - 13 Jun 2025
Viewed by 511
Abstract
Background: Renal tumors in solitary kidneys require treatments that optimize both oncological and functional outcomes. Robot-assisted partial nephrectomy (RAPN) offers a balance between these needs and reduced morbidity. This study investigates the oncologic and functional outcomes of RAPN in solitary-kidney patients. Methods [...] Read more.
Background: Renal tumors in solitary kidneys require treatments that optimize both oncological and functional outcomes. Robot-assisted partial nephrectomy (RAPN) offers a balance between these needs and reduced morbidity. This study investigates the oncologic and functional outcomes of RAPN in solitary-kidney patients. Methods: We analyzed data from 1852 patients with cT1-T4N0M0 renal cell carcinoma treated by RAPN from January 2018 to June 2022. The cohort included patients with solitary kidneys based on preoperative characteristics, tumor staging and perioperative outcomes using the Trifecta criteria. Results: Of the study participants, 39 had solitary kidneys. Fifteen patients (38.6%) had an ASA score > 2, indicating a higher preoperative risk. The median PADUA score was 7 (IQR 8–9). Moreover, 28 (71.8%) patients had a chronic kidney disease stage > 2. Trifecta success was achieved in 26 (66.6%) of the cases. During a median follow-up of 36 months, tumor recurrence was observed in 12 patients (30.7%), with local recurrences in 4 (10.2%) and systemic recurrences in 8 (20.5%). A higher ASA score and global ischemic clamping were independent predictors of renal function decline at the third postoperative day and Trifecta failure. Only a higher ASA score significantly predicted a significant long-term decline in renal function. Nucleolar grade at pathological stage was the only factor significantly associated with tumor recurrence. Conclusions: RAPN is as an effective treatment for renal tumors in solitary kidneys, balancing oncological control and renal function preservation. Global ischemia and patient physical status are the most important factors influencing outcomes and highlight the importance of patient selection and tailored surgical strategies. Full article
(This article belongs to the Special Issue Advances in Renal Cell Carcinoma)
Show Figures

Figure 1

11 pages, 659 KiB  
Article
Outcomes Following Peripheral Vascular Interventions in Patients with End-Stage Renal Disease
by Amar Premdatt Gopal, Ankoor Patel, Murad Elias, Shreeya Agrawal, Priya Goyal, David Samson, Igor Laskowski, Romeo Mateo, Arun Goyal and Sateesh Babu
J. Vasc. Dis. 2025, 4(2), 23; https://doi.org/10.3390/jvd4020023 - 9 Jun 2025
Viewed by 583
Abstract
Patients with End-Stage Renal Disease (ESRD) represent a very fragile population, presenting with higher rates of complications and morbidity following vascular interventions. This study aims to analyze post-operative outcomes, such as mortality, readmissions, and amputations, in patients with Peripheral Arterial Disease (PAD) and [...] Read more.
Patients with End-Stage Renal Disease (ESRD) represent a very fragile population, presenting with higher rates of complications and morbidity following vascular interventions. This study aims to analyze post-operative outcomes, such as mortality, readmissions, and amputations, in patients with Peripheral Arterial Disease (PAD) and ESRD on dialysis. Methods: A retrospective cohort study was conducted of patients with PAD and ESRD on dialysis who underwent vascular interventions between 2015 and 2017. This study focused on post-operative outcomes, including mortality, readmissions, and amputations. The data were analyzed to identify patterns and correlations. Results: This study found that patients with PAD and ESRD have long hospital stays, high amputation rates, high readmission rates, and treatment failure. Above-knee amputation (AKA) and female gender were associated with higher mortality rates, while prior stroke was associated with higher odds of readmissions. Conclusions: This study highlights the need for further studies with larger patient populations to identify independent predictors of negative outcomes. The findings suggest that specific factors, such as AKA, female gender, and prior stroke, significantly impact post-operative outcomes in this patient population. Full article
(This article belongs to the Special Issue Peripheral Arterial Disease (PAD) and Innovative Treatments)
Show Figures

Figure 1

14 pages, 3817 KiB  
Article
Mechanism of Circadian Regulation in Ferroptosis of the BMAL1/NRF2 Pathway in Renal Ischemia–Reperfusion
by Shang Xu, Qiao Tang, Haiyang Du, Jiatao Xie, Ruoxin He, Ruiyan Wang and Qian Sun
Biomedicines 2025, 13(6), 1375; https://doi.org/10.3390/biomedicines13061375 - 4 Jun 2025
Viewed by 666
Abstract
Background: Renal ischemia–reperfusion injury (IRI) is a frequent cause of kidney transplant failure. Recent studies have shown that the extent of injury is closely linked to ferroptosis, and the process of cellular ferroptosis is diurnal and regulated by circadian genes. NRF2, [...] Read more.
Background: Renal ischemia–reperfusion injury (IRI) is a frequent cause of kidney transplant failure. Recent studies have shown that the extent of injury is closely linked to ferroptosis, and the process of cellular ferroptosis is diurnal and regulated by circadian genes. NRF2, involved in iron–heme metabolism, may be related to ferroptosis. We hypothesize that the pathway plays a role in circadian regulation in ferroptosis in renal IRI. Methods: Using hematoxylin and eosin (H&E) staining, enzyme-linked immunosorbent assay (ELISA), Cell Counting Kit-8 (CCK8), flow cytometry, real-time quantitative reverse transcription PCR (qRT-PCR), and Western blotting, we analyzed renal tubular tissues in vivo and in vitro and compared the groups with IR injury treatment, inhibition of ferroptosis, and inhibition of BMAL1 gene expression at the ZT0 (zeitgeber time 0) and ZT12 (zeitgeber time 12) time points. Results: IR injury treatments caused exacerbation of injury, both in vivo and in vitro, and were more pronounced at the ZT12 time point, which correlates with circadian rhythms. The use of the ferroptosis inhibitor (Fer-I) attenuated IR injury, suggesting that IRI is associated with ferroptosis. In contrast, reduced BMAL1-gene expression exacerbated injury, and NRF2, which is elevated in IR injury, was suppressed. Conclusions: The circadian gene BMAL1 affects the circadian rhythm of ferroptosis in renal IRI through the regulation of NRF2 and its downstream pathway. In this study, renal injury is well ameliorated by the ferroptosis inhibitor, exhibiting potential as a therapeutic agent for use in renal transplantation. Full article
(This article belongs to the Special Issue The Role of Iron in Human Diseases)
Show Figures

Figure 1

9 pages, 557 KiB  
Article
Diagnostic Value of Sirtuin-1 in Predicting Contrast-Induced Nephropathy After Percutaneous Coronary Intervention
by Melis Ardic and Cuma Bulent Gul
J. Clin. Med. 2025, 14(11), 3953; https://doi.org/10.3390/jcm14113953 - 3 Jun 2025
Viewed by 506
Abstract
Objectives: Contrast-induced acute kidney injury (CI-AKI) remains a frequent and serious complication after cardiac catheterization. Sirtuin-1 (SIRT1), a NAD+-dependent deacetylase, plays a central role in renal protection against ischemia-reperfusion injury, inflammation, and vascular dysfunction. We aimed to investigate whether serum SIRT1 levels could [...] Read more.
Objectives: Contrast-induced acute kidney injury (CI-AKI) remains a frequent and serious complication after cardiac catheterization. Sirtuin-1 (SIRT1), a NAD+-dependent deacetylase, plays a central role in renal protection against ischemia-reperfusion injury, inflammation, and vascular dysfunction. We aimed to investigate whether serum SIRT1 levels could serve as an early diagnostic biomarker for CI-AKI. Methods: This prospective case-control study included 50 patients undergoing elective percutaneous coronary intervention (PCI) for stable angina. Serum SIRT1 levels were measured at baseline, 24 h, and 72 h post-PCI. The occurrence of CI-AKI was defined by a standard rise in serum creatinine, and patients were stratified accordingly. Results: Although SIRT1 levels tended to be lower in patients who developed CI-AKI (n = 17) compared to those without (n = 33), the differences were not statistically significant at any time point (p > 0.05). However, a significant between-group difference was observed in the 72-h change in SIRT1 levels (Δ0–72 h, p = 0.037), with a greater decline in the CI-AKI group. Multivariable logistic regression also revealed a trend-level inverse association between 72-h SIRT1 levels and CI-AKI (β = −0.536, p = 0.099). Conclusions: While SIRT1 is biologically plausible as a renal protective factor, our findings suggest that serial SIRT1 measurement may offer added value as a dynamic biomarker rather than a static diagnostic tool. Confirmatory trials incorporating serial SIRT1 measurements may help translate this molecular signal into clinically actionable tools for early detection of CI-AKI. Full article
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Acute Kidney Injury)
Show Figures

Figure 1

16 pages, 5276 KiB  
Article
Hypothermia Mitigates Renal Fibrosis Through the Upregulation of PGC-1α After Ischemia–Reperfusion Injury
by Dabi Kim, Suyeon Han, Hyunsu Choi, Yoon-Kyung Chang and Dae Eun Choi
Biomedicines 2025, 13(6), 1337; https://doi.org/10.3390/biomedicines13061337 - 29 May 2025
Viewed by 486
Abstract
Background: Hypothermia has been previously reported to ameliorate acute renal injury induced by ischemia–reperfusion injury (IRI). However, its protective effects against subsequent renal fibrosis remain unclear. Objectives: The aim of this study was to determine whether hypothermia provides protection against renal ischemia–reperfusion [...] Read more.
Background: Hypothermia has been previously reported to ameliorate acute renal injury induced by ischemia–reperfusion injury (IRI). However, its protective effects against subsequent renal fibrosis remain unclear. Objectives: The aim of this study was to determine whether hypothermia provides protection against renal ischemia–reperfusion injury (IRI), and to elucidate the molecular mechanisms involved. Methods: We used a model of renal fibrosis after ischemia–reperfusion injury in mice. C57BL/6 mice were divided into the following groups: control mice and ischemia–reperfusion injury mice (at 37 °C and at 32 °C). Their kidneys were harvested on day 1, day 3, and day 7 after IRI. The molecular mechanisms were evaluated. Results: The blood urea nitrogen (BUN) levels, serum creatinine (s-Cr) levels, and the histologic renal injury scores were significantly lower in the 32 °C IRI group than in the 37 °C ischemia–reperfusion injury group. In the hypothermic IR group, TGF-β and α-SMA were significantly decreased, while the PGC-1α level was significantly increased. Cold preparation increased the PGC-1α levels in HK2 cells. In TGF-β-treated HK2 cells, cold preparation decreased α-SMA and collagen IV levels. In addition, siPGC-1α in HK2 cells increased α-SMA and collagen IV, despite cold preparation. Conclusions: Hypothermia attenuates renal function deterioration and renal fibrosis in renal IRI mice kidneys. PGC-1α may play a role in hypothermic protection in renal fibrosis after IRI. Full article
Show Figures

Figure 1

20 pages, 1329 KiB  
Review
Mitochondrial Dysfunction: The Silent Catalyst of Kidney Disease Progression
by Nikola Pavlović, Marinela Križanac, Marko Kumrić, Katarina Vukojević and Joško Božić
Cells 2025, 14(11), 794; https://doi.org/10.3390/cells14110794 - 28 May 2025
Cited by 2 | Viewed by 2516
Abstract
Mitochondrial dysfunction is a pivotal driver in the pathogenesis of acute kidney injury (AKI), chronic kidney disease (CKD), and congenital anomalies of the kidney and urinary tract (CAKUT). The kidneys, second only to the heart in mitochondrial density, rely on oxidative phosphorylation to [...] Read more.
Mitochondrial dysfunction is a pivotal driver in the pathogenesis of acute kidney injury (AKI), chronic kidney disease (CKD), and congenital anomalies of the kidney and urinary tract (CAKUT). The kidneys, second only to the heart in mitochondrial density, rely on oxidative phosphorylation to meet the high ATP demands of solute reabsorption and filtration. Disrupted mitochondrial dynamics, such as excessive fission mediated by Drp1, exacerbate tubular apoptosis and inflammation in AKI models like ischemia–reperfusion injury. In CKD, persistent mitochondrial dysfunction drives oxidative stress, fibrosis, and metabolic reprogramming, with epigenetic mechanisms (DNA methylation, histone modifications, non-coding RNAs) regulating genes critical for mitochondrial homeostasis, such as PMPCB and TFAM. Epigenetic dysregulation also impacts mitochondrial–ER crosstalk, influencing calcium signaling and autophagy in renal pathology. Mitophagy, the selective clearance of damaged mitochondria, plays a dual role in kidney disease. While PINK1/Parkin-mediated mitophagy protects against cisplatin-induced AKI by preventing mitochondrial fragmentation and apoptosis, its dysregulation contributes to fibrosis and CKD progression. For instance, macrophage-specific loss of mitophagy regulators like MFN2 amplifies ROS production and fibrotic responses. Conversely, BNIP3/NIX-dependent mitophagy attenuates contrast-induced AKI by suppressing NLRP3 inflammasome activation. In diabetic nephropathy, impaired mitophagy correlates with declining eGFR and interstitial fibrosis, highlighting its diagnostic and therapeutic potential. Emerging therapeutic strategies target mitochondrial dysfunction through antioxidants (e.g., MitoQ, SS-31), mitophagy inducers (e.g., COPT nanoparticles), and mitochondrial transplantation, which mitigates AKI by restoring bioenergetics and modulating inflammatory pathways. Nanotechnology-enhanced drug delivery systems, such as curcumin-loaded nanoparticles, improve renal targeting and reduce oxidative stress. Epigenetic interventions, including PPAR-α agonists and KLF4 modulators, show promise in reversing metabolic reprogramming and fibrosis. These advances underscore mitochondria as central hubs in renal pathophysiology. Tailored interventions—ranging from Drp1 inhibition to mitochondrial transplantation—hold transformative potential to mitigate kidney injury and improve clinical outcomes. Additionally, dietary interventions and novel regulators such as adenogens are emerging as promising strategies to modulate mitochondrial function and attenuate kidney disease progression. Future research should address the gaps in understanding the role of mitophagy in CAKUT and optimize targeted delivery systems for precision therapies. Full article
Show Figures

Figure 1

24 pages, 21945 KiB  
Article
Drug Pair of Astragali Radix–Ligustri Lucidi Fructus Alleviates Acute Kidney Injury in Mice Induced by Ischemia–Reperfusion Through Inhibiting Ferroptosis
by Xuanhe Liu, Dan Zhang, Yuting Xie, Mengdan Wang, Xiaochun Chen, Weijie Yu, Yuming Ma, Jia Zeng, Qixuan Long, Guangrui Huang, Jie Geng and Anlong Xu
Pharmaceuticals 2025, 18(6), 789; https://doi.org/10.3390/ph18060789 - 25 May 2025
Viewed by 763
Abstract
Background: Acute kidney injury (AKI), characterized by high morbidity and mortality, is primarily caused by renal ischemia–reperfusion injury (RIRI). Ferroptosis plays a key role in RIRI, yet its underlying mechanisms remain unclear. The drug pair of Astragali Radix–Ligustri Lucidi Fructus (DAL) shows promise [...] Read more.
Background: Acute kidney injury (AKI), characterized by high morbidity and mortality, is primarily caused by renal ischemia–reperfusion injury (RIRI). Ferroptosis plays a key role in RIRI, yet its underlying mechanisms remain unclear. The drug pair of Astragali Radix–Ligustri Lucidi Fructus (DAL) shows promise in renal diseases, but its protective effects against RIRI and associated molecular pathways via ferroptosis inhibition are unknown. This study aimed to investigate DAL’s therapeutic effects on RIRI and its mechanisms. Methods: A mouse model of bilateral renal ischemia–reperfusion was established. Renal function (serum creatinine, Scr; blood urea nitrogen, BUN), inflammatory cytokines (TNF-α, IFN-γ, IL-6), ferroptosis markers (GPX4, MDA, GSH, tissue iron), and pathological damage were evaluated. Transcriptomic sequencing and electron microscopy analyzed gene pathways and mitochondrial structure. In HK-2 cells, oxygen–glucose deprivation/reoxygenation (OGD/R) and RSL3-induced ferroptosis models were used to assess DAL-containing serum effects via cell viability, GPX4 expression, and mitochondrial morphology. LC-MS analyzed DAL’s chemical components, and network pharmacology predicted ferroptosis-related targets. Results: DAL significantly reduced Scr/BUN levels, alleviated tubular injury, fibrosis, and apoptosis, and downregulated inflammatory cytokines and damage markers. It inhibited ferroptosis by upregulating GPX4, decreasing MDA/tissue iron, and increasing GSH. Transcriptomics revealed enrichment in lipid metabolism pathways. DAL restored the mitochondrial cristae structure; DAL-containing serum improved cell viability, blocked RSL3-induced GPX4 downregulation, and mitigated mitochondrial dysfunction. Network pharmacology identified DAL’s potential active components and targets. Molecular docking validated binding affinity and interaction patterns of active components with targets. Conclusions: DAL protects against RIRI by upregulating GPX4, preserving the mitochondrial structure, and inhibiting ferroptosis, highlighting its therapeutic potential for AKI prevention and treatment. Full article
(This article belongs to the Special Issue New Development in Pharmacotherapy of Kidney Diseases)
Show Figures

Figure 1

8 pages, 192 KiB  
Article
The Influence of 3D Technology Integration on Laparoscopic Partial Nephrectomy Practice and Surgical Outcomes
by Markos Karavitakis, Nikolaos Grivas, Christos Zabaftis, Filippos Nikitakis, Smaragda Tsela, Ioannis Leotsakos, Ioannis Katafigiotis and Dionysios Mitropoulos
Curr. Oncol. 2025, 32(6), 297; https://doi.org/10.3390/curroncol32060297 - 23 May 2025
Viewed by 419
Abstract
Partial nephrectomy (PN) is the standard treatment for renal cell carcinoma (RCC), offering cancer control with renal preservation. Three-dimensional laparoscopy addresses the limitations of traditional two-dimensional systems by enhancing depth perception and accuracy. This study evaluates the impact of 3D laparoscopy on PN [...] Read more.
Partial nephrectomy (PN) is the standard treatment for renal cell carcinoma (RCC), offering cancer control with renal preservation. Three-dimensional laparoscopy addresses the limitations of traditional two-dimensional systems by enhancing depth perception and accuracy. This study evaluates the impact of 3D laparoscopy on PN for larger and complex tumors. We retrospectively analyzed 200 laparoscopic nephrectomies by a single surgeon between 2020 and 2024, comparing pre-3D and post-3D groups (100 cases each). Key outcomes included the rate of PN, warm ischemia time (WIT), and operative time. The post-3D group demonstrated a significant increase in PN for tumors >4 cm (48% vs. 35%, p = 0.028) and high RENAL scores ≥8 (41% vs. 29%, p = 0.035). Median WIT was significantly shorter (24 min vs. 29 min, p = 0.018 for larger tumors; 26 min vs. 32 min, p = 0.022 for high complexity). Total operative time was also reduced (175 min vs. 195 min, p = 0.031). Positive surgical margins were lower in the post-3D group (0% vs. 2%), and complication rates were comparable (5% vs. 4%, p = 0.712). Three-dimensional laparoscopy significantly improves the feasibility and precision of PN for larger and complex tumors, enhancing outcomes without increasing complications. Full article
(This article belongs to the Section Genitourinary Oncology)
19 pages, 5960 KiB  
Article
Coixol Protects Against Acute Kidney Injury by Reducing Cell Senescence
by Kang Li, Xiaoxue Wang, Huidi Tang, Feifan Wang, Zetong Qu, Xiaojie Wang, Xiang Li and Xiaoqing Cao
Biology 2025, 14(5), 560; https://doi.org/10.3390/biology14050560 - 17 May 2025
Viewed by 814
Abstract
Acute kidney injury (AKI) is associated with increased in-hospital mortality, yet effective therapeutic agents remain limited. Coixol, a polyphenolic compound derived from Coix, possesses anti-inflammatory properties, but its role in AKI remains unclear. In this study, we demonstrate that Coixol exerts protective effects [...] Read more.
Acute kidney injury (AKI) is associated with increased in-hospital mortality, yet effective therapeutic agents remain limited. Coixol, a polyphenolic compound derived from Coix, possesses anti-inflammatory properties, but its role in AKI remains unclear. In this study, we demonstrate that Coixol exerts protective effects against ischemia/reperfusion (I/R)-induced AKI by alleviating cellular senescence. Coixol treatment significantly reduced serum creatinine (SCr) and blood urea nitrogen (BUN) levels and decreased the expression of KIM1 and NGAL. RNA sequencing and validation experiments revealed that Coixol suppressed cellular senescence in AKI. Through a weighted gene co-expression network analysis and machine learning, we identified Plaur as a key target of Coixol, which was further validated using RNA-seq data. Notably, Plaur overexpression in AKI mice diminished the protective effects of Coixol, confirming its crucial role. Additionally, molecular docking and molecular dynamics simulations demonstrated strong binding affinity between Coixol and Plaur. These findings highlight Coixol as a promising renal protective agent targeting Plaur and cellular senescence in AKI. Full article
(This article belongs to the Section Medical Biology)
Show Figures

Graphical abstract

Back to TopTop